Search Results
Your search for ,kEY matches 7151 pages
Showing 2551 - 2600Effect of Invitation to Colonoscopy Screening on Risk of Colorectal Cancer and Risk of Mortality: The NordICC Trial
In a pragmatic trial reported in The New England Journal of Medicine, Bretthauer et al, on behalf of the Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group, found a reduced risk of colorectal cancer diagnosis but no significant reduction in disease-specific mortality among...
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
Managing Primary Prophylactic Colony-Stimulating Factor Use in Patients Receiving Regimens Associated With Intermediate Risk for Febrile Neutropenia
In a study reported in the Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, FASCO, and colleagues found that a standing order entry (SOE) for vs an alert against use of primary prophylactic colony-stimulating factor (PP-CSF) for patients receiving first-line regimens for cancer associated...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?
The KRAS G12C inhibitor sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of disease progression or death by 34% compared with standard second-line docetaxel for patients with previously treated non–small cell lung cancer (NSCLC) and KRAS G12C mutations....
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
PSA Screening Rates and Incidence of Metastatic Prostate Cancer at VHA Facilities
In a retrospective cohort study reported in JAMA Oncology, Bryant et al found that prostate-specific antigen (PSA) screening rates at Veterans Health Administration (VHA) facilities declined between 2005 and 2019—and that diagnoses of metastatic prostate cancer increased over the same time period....
Genomic Microsatellite Signature Assay to Identify Germline MMRD in Patients With CMMRD
In an analysis reported in the Journal of Clinical Oncology, Chung et al described the performance of a newly developed assay using genomic microsatellite signatures (LOGIC; low-pass genomic instability characterization) in detecting germline mismatch repair deficiency (MMRD) in patients with the...
Chemotherapy Outcomes in Noninfant Childhood ALL With 11q23/KMT2A Rearrangements
In a retrospective study reported in the Journal of Clinical Oncology, Attarbaschi et al described outcomes in patients with noninfant childhood acute lymphoblastic leukemia (ALL) and 11q23/KMT2A rearrangements treated with chemotherapy regimens between 1995 and 2010. Study Details The study...
Second-Line Therapy and Beyond in Hepatocellular Carcinoma
This is Part 2 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss second-line therapy and beyond in hepatocellular carcinoma. The...
Identifying Patients With Ovarian Cancer With Greatest Potential Benefit From First-Line Bevacizumab
In a study reported in the Journal of Clinical Oncology, Benoit You, MD, PhD, and colleagues found that an unfavorable CA-125 elimination rate constant K (KELIM) score, indicating poorer tumor chemosensitivity, was associated with derived benefit from first-line bevacizumab when given with...
First-Line Toripalimab Plus Chemotherapy in Advanced NSCLC: CHOICE-01
As reported in the Journal of Clinical Oncology by Wang et al, a Chinese phase III trial (CHOICE-01) has shown prolonged progression-free survival with the addition of the anti–PD-1 monoclonal antibody toripalimab to platinum-based chemotherapy in the first-line treatment of patients with advanced...
Phase II Trial Reports High Response Rates With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, almost two-thirds of patients with stage II to IV cutaneous squamous cell carcinoma had tumors nearly or completely eradicated by neoadjuvant treatment with cemiplimab-rwlc, an agent targeting PD-1. The results were presented at the European ...
2022 Annual Report to the Nation on the Status of Cancer Released
Overall cancer death rates continued to decline among men, women, children, adolescents, and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer...
Have Changes in Cancer Therapy Over Time Affected the Risk of Breast Cancer Among Female Childhood Cancer Survivors?
In an analysis from the Childhood Cancer Survivor Study reported in JAMA Oncology, Tara O. Henderson, MD, MPH, and colleagues found that rates of invasive breast cancer have declined over time among female survivors of childhood cancer, with the reduction appearing to be largely associated with...
Small Study Examines Repeated Convection-Enhanced Delivery of Topotecan for Recurrent Glioblastoma
In a single-center, small phase Ib trial reported in The Lancet Oncology, Spinazzi et al found that repeated and prolonged convection-enhanced delivery of topotecan prior to surgery was feasible in patients with recurrent glioblastoma and resulted in significant reduction in proliferating tumor...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men
It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...
Future Leaders Selected to Advance Gender Equality Through the Leadership Programme for Women in Oncology
The first 10 participants in the new Leadership Programme for Women in Oncology have been announced. The program, a joint endeavour from ASCO and City Cancer Challenge Foundation (C/Can), seeks to address the specific challenges and barriers faced by women leaders in oncology and strengthen the...
SIO-ASCO Guideline Proposes Evidence-Based Approaches to Pain Management Incorporating Integrative Medicine Interventions
The Society for Integrative Oncology (SIO) and ASCO have released a guideline that appraises the evidence to support incorporating integrative medicine approaches into managing pain in adults with cancer.1 The guideline builds upon existing ASCO guidelines on pain management, the growing body of...
For William L. Dahut, MD, a Career of Service in Oncology
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with William L. Dahut, MD, who is currently serving as Chief Scientific Officer for the American Cancer Society (ACS). In this role, Dr. Dahut manages all pieces of the organization’s discovery work,...
A Call for Creativity: The Shades of Gray in Delivery of Goal-Concordant Care
I continue to be struck by the creativity of medical oncologists. The reimagining of dosing, duration, or regimen composition to respond to patient symptoms or preferences is like a master chef in the kitchen. Although standardization has, with good reason, become the paragon, delivering...
AI Model Using Daily Step Counts May Help Predict Unplanned Hospitalizations During Cancer Therapy
An artificial intelligence (AI) model developed by researchers may assist in predicting the likelihood that a patient may have an unplanned hospitalization during radiation treatments for cancer. The machine-learning model uses daily step counts as a proxy to monitor patients’ health as they go...
Multicenter Study Sheds Light on Features of Invasive Lobular Carcinoma
A multicenter analysis of patients with invasive lobular carcinoma—the second most common histologic subtype of invasive breast cancer in the United States—showed that, despite its prevalence, invasive lobular carcinoma was detected later with worse outcomes vs invasive ductal carcinoma and had...
Incidence of Neurologic Side Effects From CAR-T Cell Therapy Is Higher in Patients With Hypophosphatemia, Study Finds
Patients with B-cell malignancies who had hypophosphatemia experienced a higher incidence and severity of neurologic side effects from chimeric antigen receptor (CAR) T-cell therapy, according to a study by Nowicki et al published in Cancer Immunology Research. The study results imply that...
Incidence of Cutaneous Adverse Events With Adjuvant PI3K Inhibitor Therapy
In a systematic review and meta-analysis reported in JAMA Oncology, Jfri et al identified risk for cutaneous adverse events among patients with cancer receiving adjuvant phosphoinositide 3-kinase (PI3K) inhibitor therapy. Study Details The analysis included 15 phase II or III randomized controlled...
Effect of Goals-of-Care Program for Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic
As reported in the Journal of Clinical Oncology by David Hui, MD, MSc, and colleagues, an interdisciplinary goals-of-care program instituted at The University of Texas MD Anderson Cancer Center in response to anticipated COVID-19–related increases in need for intensive care unit (ICU) use resulted ...
Intensive Chemoresection With Mitomycin to Reduce the Need for Surgical Procedures in Patients With Recurrent Non–Muscle-Invasive Bladder Cancer
In a Danish study (DaBlaCa-13) reported in the Journal of Clinical Oncology, Lindgren et al found that short-term intensive chemoresection with mitomycin reduced the need for surgical procedures in patients with recurrent non–muscle-invasive bladder cancer. Study Details The trial was conducted at...
Responses to Irinotecan, Temozolomide, Dinutuximab, and GM-CSF Regimen in Patients With Relapsed High-Risk Neuroblastoma
In a U.S. retrospective study reported in the Journal of Clinical Oncology, Lerman et al found that half of patients with relapsed high-risk neuroblastoma had an objective response to a regimen comprising irinotecan, temozolomide, dinutuximab, and granulocyte-macrophage colony-stimulating factor...
Study Examines Efficacy, Cost of FIT vs Multitarget Stool DNA Testing for Colorectal Cancer Screening
Commercially available noninvasive screening tests for colorectal cancer—the fecal immunochemical test (FIT) and the Cologuard multitarget stool DNA test—are equally effective for screening patients with early-stage colorectal cancer. However, FIT costs about one-fifth of the multitarget stool DNA...
Timely Surveillance With Chest Imaging May Benefit Patients With Metastatic Colorectal Cancer
Patients with colorectal cancer who have certain clinical characteristics may benefit from more frequent chest imaging to help identify and target cancer that has metastasized to the lungs, according to a new study presented at the 2022 Scientific Forum of the American College of Surgeons Clinical...
Pembrolizumab With or Without Chemotherapy vs Cetuximab/Chemotherapy in Recurrent or Metastatic Head and Neck Cancer
As reported in the Journal of Clinical Oncology by Kevin Harrington, MD, PhD, and colleagues, updated results of the phase III KEYNOTE-048 trial showed enduring survival benefits with first-line pembrolizumab alone and pembrolizumab/chemotherapy vs cetuximab/chemotherapy in patients with recurrent...
Study Identifies How Cancer-Causing Gene Might Regulate Genetic Variation in Prostate Cancer
Researchers at the Barts Cancer Institute at the Queen Mary University of London, the Italian Institute for Genomic Medicine, and the University of Milan may have identified a novel role for a cancer-causing gene in controlling an important genetic process that underpins genetic variation in...
First-Line Nivolumab/Ipilimumab vs Chemotherapy in Metastatic NSCLC Without EGFR or ALK Alterations: 5-Year Survival
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, MSc, FASCO, and colleagues, a 5-year analysis of the phase III CheckMate 227 trial showed improvement in overall survival with first-line nivolumab/ipilimumab vs platinum-doublet chemotherapy, at ≥ 3 years after cessation of...
Prevalence of and Risks for Thoracic Soft-Tissue Sarcomas in Breast Cancer Survivors
In a retrospective cohort study reported in The Lancet Oncology, Veiga et al found that receipt of radiotherapy was the strongest risk factor for development of thoracic soft-tissue sarcomas in U.S. breast cancer survivors; both hypertension and diabetes were significant risk factors for...
Financial Hardship Among Adult Survivors of Childhood Cancer After Implementation of the Affordable Care Act
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Nathan et al found that adult survivors of childhood cancer were more likely to report financial hardship than siblings without cancer in the era following implementation of the Affordable Care...
MONALEESA Analyses Show Widespread Benefit for Ribociclib in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Further analyses of the MONALEESA metastatic breast cancer trials have shown that the benefit of ribociclib plus endocrine therapy in the first-line setting extends to most intrinsic molecular subtypes and is consistent across multiple subgroups. The studies were presented at the 2021 San Antonio...
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer
Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...
Long-Term Outcomes With Minimal-Access vs Conventional Breast Surgery in Stage 0 to III Breast Cancer
In a Chinese single-center, retrospective cohort, propensity score–matched analysis reported in JAMA Surgery, Wan et al found no difference in long-term outcomes, including distant metastasis–free and overall survival, with minimal-access breast surgery vs conventional breast surgery in women with...
Polycystic Ovary Syndrome and Risk of Pancreatic Cancer
In a single-center case-control study reported as a research letter in JAMA Oncology, Peeri et al found that women with polycystic ovary syndrome (PCOS) may be at an increased risk of developing pancreatic cancer. Study Details The study involved data from the Memorial Sloan Kettering Cancer Center ...
Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma
In a Chinese single-center phase II trial reported in JAMA Surgery, Wu et al found neoadjuvant intensity-modulated radiotherapy (IMRT) followed by hepatectomy could be an effective treatment option in patients with centrally located hepatocellular carcinoma. Study Details In the study, 38 patients...
Risk of Meningioma in Childhood Cancer Survivors
In a pooled analysis reported in JAMA Oncology, Withrow et al found that increased exposure of the meninges to radiation therapy was associated with an increased risk of developing meningioma in survivors of childhood cancer. Receipt of methotrexate was also associated with increased risk. Study...
Palliative Care Use Among Commercially Insured U.S. Patients With Metastatic Cancer: 2001–2016
In a study reported in JCO Oncology Practice, Ferrario et al found that while use of palliative care among commercially insured patients aged 25 to 64 years in the United States with metastatic cancer has increased since 2001, use remained at 40% among patients with very poor–prognosis cancers in...
Association of Autoantibodies to Gastric Mucosa and Risk of Gastric Cancer
In a case-control study reported in JAMA Oncology, Minkyo Song, MD, PhD, and colleagues found that seropositivity for gastric antiparietal cell antibodies (APCAs) was associated with an increased risk of gastric cancer among younger Finnish women who were seronegative for antibodies to Helicobacter ...
Effect of Social Factors on Cancer Screening Rates Across U.S. Counties
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
Eligibility for Lung Cancer Screening Among Women With a Smoking History Undergoing Breast Cancer Screening
In a single-center retrospective cohort study reported in JAMA Network Open, Titan et al identified the proportion of women with a history of smoking undergoing breast cancer screening with mammography who were eligible for low-dose computed tomography (CT) lung cancer screening, as well as the...
